For the first time, Lilly will supply API at a
significantly reduced price along with pro-bono technical
assistance, enabling EVA Pharma to manufacture and supply insulin
to at least one million people in lower income countries
INDIANAPOLIS and CAIRO, Dec. 14,
2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:
LLY) and EVA Pharma announced today a collaboration to deliver a
sustainable supply of high-quality, affordable human and analogue
insulin to at least one million people living with type 1 and type
2 diabetes in low- to middle-income countries (LMICs), most of
which are in Africa.
In a first for Lilly, the company will supply its active
pharmaceutical ingredient (API) for insulin at a significantly
reduced price to EVA Pharma. Lilly will also provide a pro-bono
technology transfer to enable EVA Pharma to formulate, fill and
finish insulin vials and cartridges – establishing the company as a
trusted manufacturer of these lifesaving products in Africa.
EVA Pharma expects to begin distribution of the African-made
insulin products within 18 months and to reach one million people
per year by 2030. This collaboration is part of the Lilly 30x30
initiative, which aims to improve access to quality healthcare for
30 million people living in limited-resource settings, annually, by
2030.
"Our new collaboration with EVA Pharma reflects Lilly's deep
commitment to making equitable and affordable access to insulin a
reality for people living with diabetes in low- and middle-income
countries," said Ilya Yuffa,
president of Lilly International. "This latest initiative from
Lilly will empower local manufacturing, finishing and distribution
of quality insulin – in Africa –
which will transform communities and make life better for people
throughout the continent."
"EVA Pharma is committed to empowering the fight for health
and well-being as a human right," said Riad Armanious, CEO of EVA Pharma. "People
suffering from diabetes in LMICs experience daily challenges in
accessing treatment. We feel blessed to collaborate with the team
at Lilly. Combining our African reach, state-of-the-art facilities,
and Lilly's deep expertise in diabetes care, we aim to treat at
least one million patients by 2030 who otherwise may not have
access to life-saving medication."
According to the IDF Diabetes Atlas, the total number of people
with diabetes in Africa is
expected to increase 129% by 2045, reaching 55 million people.
WHO established the Global Diabetes Compact in 2021, a global
initiative to support countries in implementing effective programs
for the prevention and management of diabetes, one tenet of which
includes engaging with the private sector to expand access to
products that will improve the lives of people living with
diabetes. The dialogues with WHO encourage implementation of and
accountability for the commitments and contributions toward
improving access to insulin.
"The success of these commitments to increase access for people
living with diabetes is an important step in the right direction,
but global engagement will need to be translated into
implementation in regions and countries," said WHO Director for
Noncommunicable Disease, Dr Bente
Mikkelsen. "This is the starting point – the hope is to have
insulin and diabetes devices as part of Essential Benefit Packages
in low- and middle-income countries towards achieving Universal
Health Coverage."
Lilly will work with EVA Pharma to ensure that their products
meet the high-quality standards set for WHO prequalification, which
has become a global symbol for safety, quality and efficacy.
About Lilly
Lilly unites caring with discovery to
create medicines that make life better for people around the world.
We've been pioneering life-changing discoveries for nearly 150
years, and today our medicines help more than 47 million
people across the globe. Harnessing the power of biotechnology,
chemistry and genetic medicine, our scientists are urgently
advancing new discoveries to solve some of the world's most
significant health challenges, redefining diabetes care, treating
obesity and curtailing its most devastating long-term effects,
advancing the fight against Alzheimer's disease, providing
solutions to some of the most debilitating immune system disorders,
and transforming the most difficult-to-treat cancers into
manageable diseases. With each step toward a healthier world, we're
motivated by one thing: making life better for millions more
people. That includes delivering innovative clinical trials that
reflect the diversity of our world and working to ensure our
medicines are accessible and affordable. To learn more,
visit Lilly.com and Lilly.com/newsroom or
follow us on Facebook, Instagram and LinkedIn. C-LLY
About EVA Pharma
EVA Pharma empowers the fight for
health and well-being in communities around the world. With a
5,000-strong team of professionals, the company produces more than
one million healthcare products a day at its state-of-the-art
manufacturing facilities, which are equipped with cutting-edge
technology, are internationally recognized for innovation, and have
been approved by multiple regulatory agencies.
The company's product portfolio focuses on pressing, yet unmet,
disease areas, such as diabetes and cardiovascular diseases,
oncology, neuroscience, ophthalmology, anti-infectives, bone and
pain, hepatology, and reproductive health, to meet both local and
international demand.
EVA Pharma is one of the fastest-growing healthcare companies in
the Middle East and Africa, with an extensive pan-African
presence, while operating in more than 40 countries worldwide.
For more information, please visit: www.evapharma.com &
https://www.evapharma.com/newsroom or follow us on Facebook,
LinkedIn & Instagram.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about a collaboration between Lilly and EVA Pharma and its
potential benefits and reflects Lilly's current beliefs and
expectations. However, as with any such undertaking, there are
substantial risks and uncertainties in the process of drug
research, development and commercialization. Among other things,
there can be no guarantee that Lilly will realize the expected
benefits of the collaboration, that the collaboration will succeed,
or that Lilly will execute its strategy as expected. For further
discussion of these and other risks and uncertainties that could
cause actual results to differ from Lilly's expectations, see
Lilly's Form 10-K and Form 10-Q filings with the United States
Securities and Exchange Commission. Except as required by law,
Lilly undertakes no duty to update forward-looking statements to
reflect events after the date of this release.
Refer to:
|
Carrie Munk,
munk_carrie@lilly.com; 317-416-2939
|
|
Ahmed Ellewa,
ahmed.ellewa@evapharma.com; +20-1000-053-643
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-and-eva-pharma-announce-collaboration-to-enhance-sustainable-access-to-affordable-insulin-in-africa-301702316.html
SOURCE Eli Lilly and Company